Develops drugs for rare diseases like paroxysmal nocturnal hemoglobinuria.
Jun 2026Revenue $646K/yrExpenses $28.4M/yr
No trend
Figures by year
When will Rallybio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $646K and expenses $28.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $858K | $33.9M | −$33.1M |
| Dec 2024 | $636K | $61.1M | −$60.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.